Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

INCLUSION CRITERIA:

   - Diagnosis of previously untreated stage I or IIA Hodgkin's lymphoma, eligible subtypes

      - Nodular sclerosis

      - Mixed cellularity

      - Classical, not otherwise specified

   - Age ≥ 18 years and ≤ 70 years

   - Granulocytes ≥ 2 x 10e6/µL

   - Platelets ≥ 150 x 10e6/µL

   - Bilirubin ≤ 2.5 mg/dL

   - Serum creatinine ≤ 2 mg/dL

   - Patients > 50 years or those with a history of cardiac disease should have an ejection
   fraction ≥ 50%

   - All scans, X-rays, laboratory tests must be performed within 6 weeks of enrollment

   - Pathologic material reviewed at Stanford University

   - Evaluation by Stanford Medical Oncology and Radiation Oncology with review at the
   Hodgkin's Disease Staging Conference

   - Written informed consent

EXCLUSION CRITERIA:

   - Lymphocytic predominance Hodgkin's disease

   - Prior treatment for Hodgkin's disease

   - Mediastinal mass equal to or greater than one-third the maximum intrathoracic diameter
   on a standing posteroanterior chest x-ray

   - Any lymph node mass > 10 cm in greatest trans-axial diameter

   - Two or more extranodal sites of disease

   - Constitutional (B) symptoms present at diagnosis

   - Prior or concurrent malignancies within 5 years (EXCEPTION: basal cell carcinoma of
   the skin)

   - Any medical contraindication to the planned treatment, including:

      - Pregnant

      - Positive antibody test for the human immunodeficiency virus (HIV)